New hope for kids with Tough-to-Treat TB: safety study paves way for better dosing
NCT ID NCT02906007
Summary
This study aimed to find safe and effective doses of the drug bedaquiline for children and adolescents with a hard-to-treat form of tuberculosis (TB) that resists standard antibiotics. It involved 54 young participants, from infants to teens, who also received their standard TB treatment. Researchers closely monitored how the children's bodies processed the drug and checked for any side effects over 24 weeks.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Desmond Tutu TB Centre - Stellenbosch University (DTTC-SU) CRS
Cape Town, Western Cape, 7505, South Africa
-
Les Centres GHESKIO Clinical Research Site (GHESKIO-INLR) CRS
Port-au-Prince, HT-6110, Haiti
-
PHRU Matlosana CRS
Klerksdorp, North West, 2574, South Africa
-
Sizwe CRS
Johannesburg, Gauteng, South Africa
Conditions
Explore the condition pages connected to this study.